IMW 2019 | Is panobinostat plus VD a successful combination for relapsed MM?

Sarah Bird

Sarah Bird, MD, of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, discusses the combination of panobinostat, bortezomib and dexamethasone (PanVD) for very heavily pre-treated multiple myeloma in the real world. She indicates both the positive and negative outcomes of the study, and highlights the need for effective treatments for heavily pre-treated patients. This research was presented in a poster session at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

Share this video